KML29 and Gabapentin Were Synergistic for Cold Allodynia but Additive for Mechanical Allodynia
Combining KML29 with gabapentin produced different interaction and tolerance patterns across two mouse pain-related tests. Synergy for cold allodynia did not mean synergy for mechanical allodynia, or equal durability on both measures.
The combination acted on two different intervention routes
KML29 inhibits monoacylglycerol lipase, an enzyme involved in endocannabinoid breakdown. Gabapentin was the comparator analgesic. In a nerve-injury model, the low-dose combination additively reduced mechanical allodynia and synergistically reduced cold allodynia. Additive and synergistic are specific interaction descriptions, not interchangeable synonyms for improvement.
Repeated treatment produced another endpoint difference
Mechanical effects did not undergo tolerance under the studied repeated regimen, whereas cold-allodynia effects showed mild tolerance. The initially stronger interaction therefore did not establish more durable benefit. Rimonabant also partially reversed the mechanical effect but not the cold effect, supporting further differences in the measured responses.
Receptor density and function did not move together
High-dose KML29 alone reduced CB1 expression and function. The combination reduced receptor density without altering the assessed function. Thus, fewer binding sites did not establish the same signaling change as high-dose monotherapy. Spinal lipid and whole-brain receptor measurements also represent different biological samples.
Interpreting the evidence
The study supports a specified preclinical combination strategy with selective findings. It does not establish that gabapentin and marijuana share this interaction, prevent tolerance or provide safe human co-treatment.
Related reading: consequences of changing endocannabinoid breakdown.
Research reference
Crowe MS; Wilson CD; Leishman E; et al. (2017). The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. British journal of pharmacology. doi:10.1111/bph.14055. Evidence basis: study abstract.
